Entrada Therapeutics Reports 0.10% Mean Dystrophin Increase In 5 mg/kg Cohort Of Phase 1/2 Duchenne Trial Of ENTR-601-45; Primary Safety Goal Met

Loading news article.

Entrada Therapeutics Reports 0.10% Mean Dystrophin Increase In 5 mg/kg Cohort Of Phase 1/2 Duchenne Trial Of ENTR-601-45; Primary Safety Goal Met | WAPE

Entrada Therapeutics Reports 0.10% Mean Dystrophin Increase In 5 mg/kg Cohort Of Phase 1/2 Duchenne Trial Of ENTR-601-45; Primary Safety Goal Met

Article summary

Related companies

Analyzed by WAPE AI.

Comments —